The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer

The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer - The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009746

Enrollment

Registered

2013-01-10

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Dendritic cell-based vaccine (day 1)+ LAK immunotherapy (day 1) Q2weeks, 6 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically determined lung cancer 2. Histologically determined highly expression of MUC1 in cancer cells 3. Refractory for standard anti-cancer treatments 4. Aged 20-85 years old 5. ECOG performance status 0-2 6. No prior anti-cancer treatments within 4 weeks 7. Adequate organs function 8. Written informed consent

Exclusion criteria

Exclusion criteria: 1) Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency ) 2) Active infections 3) Active simultaneous cancer 4)Massive pleural or pericardial effusion 5) Concurrent treatment with steroids or immunosuppressing agent 6) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Immunological monitoring	—

Secondary

Measure	Time frame
Anti-tumor effect Disease-free survival Overall survival Safety	—

Countries

Japan

Contacts

Public ContactKoji Teramoto

Shiga University of Medical Science Department of Clinical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026